Author

Fortunato Ciardiello

Professore di oncologia medica, seconda universit

Biography

Dr. Fortunato Ciardiello is an Associate professor in the Oncologia Medica, Dipartimento Medico-Chirurgico di Internistica Clinica e Sperimentale F. Magrassi e A. Lanzara, Seconda Università degli Studi di Napoli, Naples, Italy. His study interests major on Oncological Medicine. In recent years, he has studied several on oncologia, Cancer. Currently, Dr. Ciardiello is the author/editors/reviewer in several international journals. He published 50 articles in many journals and the articles are informative and got good citations.
Title
Cited by
Year
Trifluridine/tipiracil plus bevacizumab for third-line treatment of refractory metastatic colorectal cancer: The phase 3 randomized SUNLIGHT study.
J Tabernero, GW Prager, M Fakih, F Ciardiello, E Van Cutsem, E Elez, ...Journal of Clinical Oncology 41 (4_suppl), 4-4, 2023202
27
2023
Trifluridine–tipiracil and bevacizumab in refractory metastatic colorectal cancer
GW Prager, J Taieb, M Fakih, F Ciardiello, E Van Cutsem, E Elez, ...New England Journal of Medicine 3 (1), 1657-1667, 2023202
8
2023
BREAKWATER safety lead-in (SLI): Encorafenib (E) + cetuximab (C) + chemotherapy for BRAFV600E metastatic colorectal cancer (mCRC).
S Kopetz, T Yoshino, TW Kim, R Yaeger, J Desai, HS Wasan, ...Journal of Clinical Oncology 41 (4_suppl), 119-119, 20220
3
2023
Pretreatment Plasma Circulating Tumor DNA RAS/BRAF Mutational Status in Refractory Metastatic Colorectal Cancer Patients Who Are Candidates for Anti-EGFR Rechallenge Therapy: A …
D Ciardiello, S Napolitano, V Famiglietti, L Esposito, V De Falco, ...Cancers 15 (7), 117, 030
2
2023
Efficacy and safety of a biomarker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RAS/BRAF wild type tumors at start of first line: The …
G Martini, D Ciardiello, S Napolitano, E Martinelli, T Troiani, TP Latiano, ...Frontiers in Oncology 13, 1069370, 030
2
2023
FASN multi-omic characterization reveals metabolic heterogeneity in pancreatic and prostate adenocarcinoma
U Chianese, C Papulino, A Ali, F Ciardiello, S Cappabianca, L Altucci, ...Journal of translational medicine 2 (), -5, 2023202
1
2023
Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer
Final results of DESTINY-CRC0 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancerT Yoshino, M Di Bartolomeo, K Raghav, T Masuishi, F Loupakis, ...Nature Communications 4 (), 3332, 2023202
1
2023
Brief Report: Canadian Cancer Trials Group IND. 227: A Phase 2 Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma (NCT02784171)
Brief Report: Canadian Cancer Trials Group IND. 227: A Phase 2 Randomized Study of Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma (NCT027847)MC Piccirillo, Q Chu, P Bradbury, W Tu, CH Coschi, F Grosso, M Florescu, ...Journal of Thoracic Oncology 8 (6), 83-89, 2023202
1
2023
Panitumumab Plus Trifluridine-Tipiracil as Anti–Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 …
S Napolitano, V De Falco, G Martini, D Ciardiello, E Martinelli, ...JAMA oncology, 2023202
1
2023
Impact of Epstein Barr Virus Infection on Treatment Opportunities in Patients with Nasopharyngeal Cancer
F Perri, F Sabbatino, A Ottaiano, R Fusco, M Caraglia, M Cascella, ...Cancers 5 (5), 626, 2023202
1
2023
Real‐world clinical outcome and safety of adjuvant therapy in stage III melanoma patients: Data from two Academic Italian Institutions
V De Falco, G Suarato, R Napolitano, G Argenziano, V Famiglietti, ...International Journal of Cancer, 2023202
1
2023
Panitumumab plus trifluridine/tipiracil as third-line anti-EGFR rechallenge therapy in chemo-refractory RAS WT metastatic colorectal cancer: The VELO randomized phase II …
S Napolitano, V De Falco, G Martini, L Esposito, V Famiglietti, E Martinelli, ...Journal of Clinical Oncology 4 (4_suppl), 29-29, 2023202
1
2023

Referred From: https://scholar.google.com/citations?hl=en&user=35gxErAAAAAJ

Cited by
Citations 70902
h-index 115
i10-index 521
Recommended Journals
Open Access Journals